Thymosin alpha-1 vs Thymosin beta-4

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicThymosin alpha-1Thymosin beta-4
What it is

A 28-amino-acid peptide with an acetylated N-terminus, originally isolated from a thymus extract; FDA describes thymalfasin as a chemically synthesized version.1

Human thymosin beta-4, also recorded as TMSB4 and TB4X in FDA’s substance registry.4

FDA status

Not FDA-approved

Not FDA-approved; FDA advised against adding it to the compounding list1,2,3

Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.1,3

Is thymosin alpha-1 FDA-approved?

Not FDA-approved

No FDA approval reported3,4

No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists a thymosin beta-4 fragment, TB-500, among withdrawn nominations, but not thymosin beta-4 itself.3,4

Is thymosin beta-4 FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin alpha-1 is not among them.5,6

Not among the six peptides the policy lists.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin beta-4 is not among them; TB-500 is a fragment of it.5,6

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists thymosin alpha-1 among substances whose nominations were withdrawn, citing a possible significant risk of immune reactions and inadequate safety information.3

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists “thymosin beta-4, fragment (LKKTETQ), also known as TB-500” among withdrawn nominations with possible safety risks. It does not list full-length thymosin beta-4.3

Kinds of studies cited

Smaller controlled human trials

  • Controlled human trial A multicenter, single-blind, randomized trial (ETASS) in 361 people with severe sepsis, in which 28-day deaths were 26% with Ta1 and 35% in the control group, a difference that was not statistically significant, described in FDA’s evaluation.1
  • Controlled human trial An exploratory, open-label, randomized trial in 488 people with advanced melanoma, and small double-blind trials in hepatitis, described in FDA’s evaluation.1
  • Animal or laboratory research Laboratory and animal studies of immune effects through Toll-like receptors, which FDA found hard to relate to people because of the high amounts used.1

Smaller controlled human trials

  • Controlled human trial A randomized, double-masked, placebo-controlled Phase 2 trial in 72 people with moderate to severe dry eye (2015).7
  • Controlled human trial A randomized, double-masked, placebo-controlled Phase 3 trial in 18 people with neurotrophic keratopathy and a persistent corneal defect (2022).8
Records collected

18 ClinicalTrials.gov records and 30 PubMed records collected

7 ClinicalTrials.gov records and 25 PubMed records collected

Area of study

Inflammation and immune, Cancer, Infections1

Eyes7,8

Latest dated events
  1. FDA’s compounding safety-risk page, as last updated, lists thymosin alpha-1 among withdrawn nominations with safety concerns.3
  2. FDA’s Pharmacy Compounding Advisory Committee votes 17 to 4 against placing thymosin alpha-1 on the list.2
  3. FDA staff date their evaluation recommending against adding thymosin alpha-1 to the 503A bulks list.1
  1. FDA’s compounding safety-risk page, as last updated, lists the TB-500 fragment but not thymosin beta-4 itself.3
  2. A Phase 3 trial of thymosin beta-4 in 18 people with neurotrophic keratopathy is published.8
  3. A Phase 2 dry eye trial of thymosin beta-4 in 72 people is published.7

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  2. 2
    December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Thymosin beta-4 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model (2015) · PMID 26056426 ↗

    Clinical Ophthalmology · Official source · Source checked November 15, 2026

  8. 8
    RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2022) · PMID 36613994 ↗

    International Journal of Molecular Sciences · Official source · Source checked November 15, 2026